Keros Therapeutics, Inc. announced an exclusive global licensing agreement with Takeda Pharmaceutical Company Limited to further develop, manufacture, and commercialize elritercept. This agreement covers all territories outside of mainland China, Hong Kong, and Macau, significantly expanding the potential reach of the investigational therapy.
Under the terms of the agreement, Keros will receive an upfront payment of $200 million from Takeda. The deal also includes potential payments for regulatory, development, and commercial sales milestones that could exceed $1.1 billion, in addition to tiered royalties on net sales.
Elritercept, a late-stage activin inhibitor, is designed to treat anemia associated with certain hematologic cancers, including myelodysplastic syndromes (MDS) and myelofibrosis. The U.S. FDA has granted Fast Track designation for elritercept's development in very low-, low-, and intermediate-risk MDS, with a Phase 3 RENEW trial expected to begin enrollment soon.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.